In adults and pediatric patients aged 10 years and older with HoFH: The initial recommended dosage of REPATHA is 420 mg once monthly administered subcutaneously [see Dosage and Administration (2.3)]
Wenjing H, Shao Y, Yu Y, Huang W, Feng G, Li J
Chipotle is one of the most GLP-1-friendly fast-casual restaurants in the country- and thats not an accident
Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies
However, individual response depends on genetic predisposition, lifestyle factors, medication timing, and whether your dose matches your metabolic needs
[8] Chemotherapy-induced peripheral neuropathy (CIPN): A review of two studies concluded that ALC may be a treatment option for paclitaxel- and cisplatin-induced CIPN, while a clinical trial showed it did not prevent CIPN and appeared to worsen the conditions in taxane therapy
